Direkt zum Inhalt

Gruber, Isabella ; Weidner, Karin ; Treutwein, Marius ; Koelbl, Oliver

Stereotactic radiosurgery of brain metastases: a retrospective study

Article

Gruber, Isabella , Weidner, Karin, Treutwein, Marius and Koelbl, Oliver (2023) Stereotactic radiosurgery of brain metastases: a retrospective study. Radiation Oncology 18 (1).

DOI to cite this document: 10.5283/epub.55259


Abstract

Background Single-fraction stereotactic radiosurgery (SRS) is an established standard for radiation therapy of brain metastases although recent developments indicate that multi-fractionated stereotactic radiotherapy (FSRT) results in lower radiation necrosis especially for larger metastases, and the same or even better local control in comparison to SRS. Methods Seventy-two patients with 111 ...

Background Single-fraction stereotactic radiosurgery (SRS) is an established standard for radiation therapy of brain metastases although recent developments indicate that multi-fractionated stereotactic radiotherapy (FSRT) results in lower radiation necrosis especially for larger metastases, and the same or even better local control in comparison to SRS. Methods Seventy-two patients with 111 brain metastases received SRS with a single dose of 18 Gy between September 2014 and December 2021. The dose prescription was either 18 Gy given to the enclosing 80% isodose with a normalization to Dmax=100% of 22.5 Gy (part I) or 18 Gy=D98, while D0.03 cc of 21.6-22.5 Gy was accepted (part II). The study retrospectively evaluated local progression-free survival (LPFS), response on the first follow-up magnetic resonance imaging (MRI), and radiation necrosis. Results Melanoma brain metastases (n=44) were the most frequent metastases. The median gross tumor volume (GTV) was 0.30 cm(3) (IQR, 0.17-0.61). The median follow-up time of all patients was 50.8 months (IQR, 30.4-64.6). Median LPFS was 23.5 months (95%CI 17.2, 29.8). The overall LPFS rates at 12-, 18-, 24- and 30 months were 65.3%, 56.3%, 46.5%, and 38.8%. Brain metastases with radioresistant histology (melanoma, renal cell cancer, and sarcoma) showed a 12-month LPFS of 60.2%, whereas brain metastases with other histology had a 12-month LPFS of 70.1%. The response of brain metastases on first follow-up MRIs performed after a median time of 47 days (IQR, 40-63) was crucial for long-term local control and survival. Eight brain metastases (7.2%) developed radiation necrosis after a median time of 18.4 months (IQR, 9.4-26.5). In multivariate analyses, a GTV>0.3 cm(3) negatively affected LPFS (HR 2.229, 95%CI 1.172, 4.239). Melanoma, renal cell cancers, and sarcoma had a lower chance of LPFS in comparison to other cancer types (HR 2.330, 95%CI 1.155, 4.699). Conclusions Our results indicate a reasonable 1-year local control of brain metastases with radiosensitive histology. Radioresistant metastases show a comparatively poor local control. Treatment refinements merit exploration to improve local control of brain metastases. Trial registration This study is retrospectively registered (ethics approval number 23-3451-104).



Involved Institutions


Details

Item typeArticle
Journal or Publication TitleRadiation Oncology
PublisherBMC
Open Access TypeDEAL (Springer Gold)
Place of PublicationLONDON
Volume18
Number of Issue or Book Chapter1
Date19 December 2023
Date of publication21 Dec 2023 07:25
InstitutionsMedicine > Lehrstuhl für Strahlentherapie
Identification Number
ValueType
10.1186/s13014-023-02389-zDOI
KeywordsSINGLE-FRACTION; LOCAL-CONTROL; FOLLOW-UP; GUIDELINES; DIAGNOSIS; TUMORS; Stereotactic radiosurgery; Fractionated stereotactic radiotherapy; Brain metastases; Brain radiation necrosis
Dewey Decimal Classification600 Technology > 610 Medical sciences Medicine
StatusPublished
RefereedYes, this version has been refereed
Created at the University of RegensburgYes
URN of the UB Regensburgurn:nbn:de:bvb:355-epub-552592
Item ID55259

Export bibliographical data

Owner only: item control page

nach oben